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Abstract: Rapid and accurate functional assignment of novel proteins is increasing in importance, given the completion of numerous 
genome sequencing projects and the vastly expanding list of unannotated proteins. Traditionally, global primary-sequence and 
structure comparisons have been used to determine putative function. These approaches, however, do not emphasize similarities in 
active site confi gurations that are fundamental to a protein’s activity and highly conserved relative to the global and more variable 
structural features. The Comparison of Protein Active Site Structures (CPASS) database and software enable the comparison of 
experimentally identifi ed ligand-binding sites to infer biological function and aid in drug discovery. The CPASS database comprises 
the ligand-defi ned active sites identifi ed in the protein data bank, where the CPASS program compares these ligand-defi ned active 
sites to determine sequence and structural similarity without maintaining sequence connectivity. CPASS will compare any set of 
ligand-defi ned protein active sites, irrespective of the identity of the bound ligand.
Key words: functional annotation, CPASS, hypothetical proteins, ligand-defi ned active sites
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Obtaining the biological function of a protein is essential for 
determining its potential as a therapeutic target and its utility as 
part of structure-based drug design effort. Furthermore, under-
standing the biological function for a protein provides the basis 
for exploring its cellular activity. An outcome of various genom-
ics efforts has been a vast growth in putative protein sequences 
that lack any experimental functional annotation.1,2 Sequence 
homology has routinely been used as a rapid approach to assign 
biological function to these hypothetical proteins or proteins of 
unknown function.3 This is based on the accepted structural bi-
ology paradigm that a similarity in sequence (≥ 30%) implies a 
corresponding similarity in both structure and function. At best, 
sequence homology provides functional assignment for ~50% 
of the proteins identifi ed in various proteomes.2,4–6 Structural 
genomics is augmenting the functional assignment of these hy-
pothetical proteins by determining the corresponding three-di-
mensional structure.7 This permits a functional assignment by 
identifying proteins of known function that exhibit a similar 
overall fold to the hypothetical protein. Structural homology 
is a more sensitive approach for assigning function, since there 
are numerous examples of proteins with similar folds that lack 
any signifi cant sequence homology.8,9 This is consistent with 
the general observation that tertiary structures are signifi cant-
ly more evolutionary stable than protein sequences.10 Never-
theless, our analyses of the scientifi c literature for protein struc-
tures of hypothetical proteins that are emerging from structural 
genomics indicate that ~60% of the reported structures corre-
spond to a novel fold or folds that can not be readily assigned to 
a biological function as determined by the authors. 
Sequence and structural homology methods primarily de-
termine ‘‘global’’ similarities between the compared proteins.7 
However, the molecular function of a protein is generally re-
stricted to its identifi ed active site, which may involve an in-
teraction with small molecular-weight ligands, nucleic acids, 
or other proteins. Maintaining the core structural component of 
the active site is essential for preserving the functional activi-
ty of the protein. As a result, protein comparisons that focus on 
global sequence and structural similarities may miss proteins 
with conserved active sites but divergent sequences and struc-
tures. Thus, a more effective means to infer a biological func-
tion of a hypothetical protein would occur through the identifi -
cation of the protein’s active site. 
Comparative analysis of protein active sites is also critical 
for a successful drug discovery program, particularly for elim-
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inating potential toxicity pathways. Drug toxicity is a common 
cause of failure during clinical trials, where undesirable pro-
tein–ligand interactions are a plausible mechanism.11 Efforts to 
eliminate potential toxicity problems are initially carried-out by 
screening for drug selectivity against a limited panel, for prac-
tical reasons, of very closely related proteins.12 These protein 
panels are usually composed of functionally identical proteins 
with high sequence and structural similarity that are identifi ed 
by traditional homology methods. Inevitably, this approach will 
miss proteins that only exhibit similarity in the structural char-
acteristics of the active site. This is particularly problematic for 
common ligand binding sites, such as ATP, that are drug discov-
ery targets and are present in functionally diverse proteins.13 
A number of methodologies are being developed to predict 
the location of active sites in novel protein structures. This is 
typically accomplished by developing structural descriptors of 
active sites for defi ned protein functional classes and then fi t-
ting these structural templates to novel folds to identify pu-
tative active sites and annotate the hypothetical proteins. A 
variety of approaches are being applied that include aligning 
structures to match a few consensus or enzymatic catalytic res-
idues,14–23 identifi cation of cavities consistent with shapes of 
known ligands,24 a sequence independent force fi eld to extract 
common active site features,25 theoretical prediction of titra-
tion curves,26 using chemical properties and electrostatic po-
tentials of amino acid residues consistent with active site char-
acteristics,27,28 neural network analysis of spatial clustering 
of residues,29 and conserved residues from multiple sequence 
alignments (phylogenetic motifs).20,30 
Nevertheless, direct experimental observation of protein–li-
gand interactions are a more reliable mechanism for the proper 
and accurate identifi cation of protein active sites. LigBase is an 
online database that aligns only active sites present in the pro-
tein data bank (PDB) that bind the identical ligand, using struc-
ture and sequence alignments.31 Similarly, there are numerous 
databases that allow searching of the PDB for compounds pres-
ent in protein–ligand complexes.32–35 Unfortunately, these da-
tabases lack the ability to globally compare an active site iden-
tifi ed for a novel protein against the entire structural database, 
irrespective of the identity of the bound ligand, to determine 
the relative similarity in the sequence and structure of the ac-
tive sites. 
Towards this end, we have implemented a database and a 
suite of programs to compare experimentally identifi ed protein 
active sites to infer biological function (Fig. 1). In this article, 
we describe the design and application of the Comparison of 
Protein Active Site Structures (CPASS) database and software 
that enables both the sequence and structural comparison of li-
gand-defi ned active sites to infer functional activity of hypo-
thetical proteins and to aid in the design of drug selectivity. 
MATERIALS AND METHODS 
Design Philosophy 
The main feature that the CPASS program is trying to cap-
ture is the similarity in the characteristics of the active site de-
fi ned by the positions and types of amino acids relative to a 
Fig. 1. Schematic diagram of the application of the CPASS database and software to aid in the assignment of biological function to hypothetical 
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bound ligand. Unlike other approaches, CPASS does not reduce 
the database to a limited collec tion of consensus templates for 
each functional family. Similarly, CPASS does not attempt to 
simulate generic features of active sites by using descriptors 
mimicking important properties of amino acids. Instead, the 
CPASS database is composed of ligand-defi ned protein active 
site structures culled from the protein data bank (PDB). 
A total of ~34,000 X-ray and NMR structures that are cur-
rently available in the PDB were analyzed for the presence of a 
bound ligand. The CPASS database is expected to be routinely 
updated. Only protein structures that contain a bound ligand are 
included in the CPASS database. Conversely, structures that do 
not contain a protein molecule, but only contain a DNA or RNA 
molecule complexed to a ligand were excluded, since they lack 
any value in the functional annotation of a protein. The identi-
fi cation of a ligand within a protein PDB fi le was determined 
by the presence of either a HET or HETNAM record. Routine-
ly, a single protein PDB fi le may contain multiple ligands. Each 
ligand was extracted separately with a uniquely defi ned active 
site in the absence of a LINK record in the PDB fi le. The LINK 
record identifi es bonded atoms from two residue types. If a pro-
tein PDB fi le contains multiple ligands with a LINK record that 
connects these ligands, then all the ligands are extracted as a 
single ligand with a single corresponding active site. As an ex-
ample, consider a PDB fi le that contains both ATP and an Mg2+ 
ion. In the absence of a LINK record that connects the phos-
phate group from ATP to the Mg2+ ion, two separate ligand co-
ordinate fi les are extracted—one for ATP and the other for the 
Mg2+ ion. The two ligand coordinate fi les are then used to iden-
tify two separate active sites around ATP and the Mg2+ ion, re-
spectively. Conversely, if a LINK record was present in the pro-
tein PDB fi le that indicates a bond between ATP and the Mg2+ 
ion, a single ligand fi le is extracted from the protein PDB fi le 
that contains the coordinates for both ATP and Mg2+ ion. This 
single fi le that contains both ligands will then be used to deter-
mine a single ligand-based active site. 
Besides the presence of small molecular-weight ligands de-
fi ned by the HET and HETNAM records, a number of protein 
PDB structures contain small peptides, DNA, or RNA sequenc-
es complexed to the protein. The CPASS database also includes 
these small peptides, DNA, and RNA sequences (13 residues) 
with the corresponding active site defi ned by these ligands. The 
presence of a peptide or small nucleic acid chain in the protein 
PDB fi le is identifi ed by the SEQRES record, where the total 
number of residues for a particular chain is ≤13 and a second 
protein chain is defi ned with >13 residues. 
Currently, ~ 42,000 protein–ligand binding sites have been 
identifi ed in the PDB. This list excludes common and abundant 
buffer reagents, salts, and solvents that generally exhibit non-
specifi c binding irrelevant to functional activity. A total of 112 
ligands are currently excluded from the CPASS database, where 
the vast majority are common ions (Na+,Cl–,SO4
–), solvents 
(water, MES, DMSO, 2-mercaptanol, glycerol), and chemical 
fragments or clusters (acetyl, methyl) (see Supplemental Table 
1). Practical considerations required removing these ligands be-
cause of the signifi cant increase in the total number of ligand-
defi ned binding-sites in the CPASS database, the negative im-
pact on the CPASS computational time, and the minimal benefi t 
to functional identifi cation. As an example, the isolated calcium 
ion (PDB Het ID: CA) is present in 2887 structures in the PDB, 
which results in a total of 7811 binding sites, which by itself 
is 30% the size of the entire CPASS library. While it would be 
benefi cial to include the functionally relevant calcium binding 
sites in CPASS, it is not feasible to differentiate between these 
sites and the numerous irrelevant calcium binding sites present 
in the various structures. Again, simply including all the calci-
um binding sites is currently impractical, especially when the 
7811 binding sites are combined with other similarly exclud-
ed ligands. Additionally, numerous X-ray structures contain re-
dundant copies of essentially identical protein–ligand structures 
based on the number of structures found within the unit cell. 
Multiple binding sites within the same structure are identifi ed 
and only one copy is maintained if the ligand-defi ned active 
sites share ≥80% sequence identity and bind the same ligand. 
Thus, the list may be reduced to ~26,000 ligand-defi ned bind-
ing sites, when these multiple copies from the same PDB coor-
dinate fi le are eliminated. 
The ligands identifi ed from protein–ligand complexes in the 
PDB are then used to determine ligand-defi ned active sites with-
in the protein structure. The amino acid residues that comprise 
an active site are identifi ed by having at least one atom that is 
≤ 6Å from any ligand atom. Thus, the ligand chemical structure 
and bound conformation determines which amino acids within 
the protein comprise the active site. Relative changes in the li-
gand conformation may result in a corresponding change in the 
composition of the ligand-defi ned active site. The impact on 
the active site defi nition depends on the magnitude of the con-
formational change and whether this change results in either 
the complete loss or gain of an interaction with a specifi c ami-
no acid. In general, ligand conformational changes have min-
imal impact on the defi nition of the residues that describe the 
active site, where residues on the 6-Å peripheral are the most 
likely to change. 
The CPASS active site defi nition contains the residue types, 
the corresponding Cα coordinate positions, and the shortest dis-
tance from any atom in the residue to any atom in the ligand (di). 
The same active site information is then obtained from a pro-
tein–ligand complex for a targeted hypothetical or novel protein 
from experimental sources. Sequence and structural similari-
ties of ligand-defi ned active sites for hypothetical or novel pro-
teins are then compared against the entire PDB derived ligand-
defi ned active sites in the CPASS database. Any differences in 
ligand conformations between the compared active sites will 
have a minimal impact on the calculated similarity, because the 
sequence and structure of only the active sites are compared. 
The ligand structure is not included in the comparison. Again, 
a ligand conformational change may simply result in the addi-
tion or exclusion of amino acid(s) residue in the active site def-
inition. Thus, two similar active site sites would not be missed 
because of ligand conformation changes, since the remainder 
of the residues present in each active site would still exhibit the 
expected similarity in sequence and structure.
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Similarity Function 
There are two uniquely critical features of the CPASS anal-
ysis of ligand-defi ned protein active sites to identify similari-
ty in structure and function. First, the CPASS analysis is inde-
pendent of the identity of the bound ligand. Although CPASS 
allows for the comparison of active sites that contain the same 
ligand, it is not necessary. The structure of the ligand is not 
used in the comparison, since it would eliminate any mean-
ing in aligning active sites with distinct but related ligands. In 
this manner, the ligand-defi ned active site obtained for the tar-
get protein can be compared against the entire CPASS data-
base (~26,000 ligand-defi ned active sites) or any subset of the 
database to obtain a meaningful alignment score. Second, the 
sequence and structure alignment of the ligand-defi ned data-
base is not dependent on the primary sequence connectivity of 
the protein. In traditional global sequence or structure homol-
ogy, the primary sequence connectivity is a fundamental com-
ponent of the alignment analysis, where the insertion of gaps 
or deleted regions between the aligned sequences or structures 
results in a scoring penalty.37,38 Since the structural organiza-
tion of a protein active site typically comprises distal sequence 
regions of the protein coming into close contact as a result of 
the three-dimensional fold, the primary sequence connectivi-
ty is not directly relevant to the sequence and structural align-
ment of an active site. 
Thus, the CPASS program determines the optimal se-
quence and structural alignment between two compared ac-
tive sites without maintaining sequence connectivity. The 
CPASS program determines the alignment of two active sites 
by maximizing a root-mean-square-difference (rmsd) weighted 
BLOSUM6239,40 scoring function (Sab):
(1)
where active site a contains n residues and is compared with 
active site b from the CPASS database, which contains m res-
idues, pi,j is the BLOSUM62 probability for amino acid re-
placement for residue i from active site a with residue j from 
active site b, ∆rmsdi,j is a corrected root-mean-square-differ-
ence in the Cα coordinate positions between residues i and j, 
and dmin/di is the ratio of the shortest distance to the ligand 
among all amino acids in the active site, compared with the 
current amino acid’s shortest distance to the ligand. Sab is only 
summed over the optimal alignment for residue i from active 
site a with residue j from active site b. It is not summed over 
all possible combinations of i and j. If the number of residues 
are not identical between active sites a and b (n ≠ m), then the 
additional residues will not have a corresponding match. Each 
residue can be used only once in the alignment. If active site 
a contains unmatched residues, then no contribution is made 
to Sab, which effectively reduces the maximal possible score 
that can be achieved for active site a. As an example, if active 
site a contains an unmatched Ala, a score of 0 is added instead 
of a possible maximum score of 4 if active site b contained an 
appropriately aligned Ala. The active sites that are being com-
pared are typically in distinct coordinate axes, and so align-
ing the coordinates in an optimal arrangement without the use 
of the primary sequence connectivity requires an iterative ap-
proximation guided by maximizing this scoring function. 
The BLOSUM62 probability matrix was chosen based 
on the reported evaluation of a number of matrixes, where 
BLOSUM62 was identifi ed as the best matrix.40 BLOSUM62 
is also widely used to construct sequence alignments and is the 
default matrix for BLAST.41 
The calculated rmsd between residues i and j is corrected by 
1 Å (∆rmsdi,j) to account for structural variations less than 1 Å
 
that are typically within the experimental accuracy of the two 
aligned structures. Similarly, squaring the Drmsdi,j weight-
ing function softens the negative impact of larger rmsd values 
(>2–5 Å ) and still allows for a positive (nonzero) contribu-
tion to the scoring function. These rmsd values are consistent 
with generally accepted measures of accuracy for predicted 
protein– ligand models and imply a potential functional rele-
vance.42 Thus, a continuous ∆rmsdi,j weighting function is cre-
ated by simply subtracting 1 Å from the observed rmsd value, 
where a negative value is set to zero. So, an observed rmsdi,j of 
1.3 Å would result in a ∆rmsdi,j of 0.3 Å
 and a resulting 0.741 
weighting function on the BLOSUM62 probability. Converse-
ly, an observed rmsdi,j < 1.0 Å
 would result in a ∆rmsdi,j of 0 
Å and a resulting 1.0 weighting function on the BLOSUM62 
probability. 
Since the active site is defi ned by a strict distance cutoff, 
relatively large errors may arise in the alignment score due 
to small structural changes that may occur at the active site 
boundary. To minimize this effect, the score is also scaled by 
the shortest distance from an amino acid in the active site to 
the ligand to de-emphasize amino acids that are at the 6-Å 
boundary. As an illustration, consider an active site of a tar-
geted protein that contains an alanine where the methyl pro-
tons are exactly at the 6-Å limit. The remaining alanine atoms 
are all beyond the 6-Å limit. The active site of a reference pro-
tein does not include this alanine as part of its active site def-
inition because the alanine methyl protons are 6.1 Å from any 
ligand atom and beyond the 6-Å limit. Thus, because of this 
0.1-Å change and the corresponding presence and absence of 
alanine in the two active site defi nitions, the similarity scoring 
function would decrease by 4.0, when these two active sites 
are compared. Assuming the shortest distance from any atom 
in the ligand to any atom in the active site is 2 Å , the impact 
on the similarity score is reduced to 1.33 by using the dmin/di 
(2 Å /6 Å ) scaling. Conversely, the distance scaling also places 
more emphasis on active site amino acids that are closer to the 
ligand and are presumably more important in both the affi nity 
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Active Site Similarities 
The CPASS program generates two outputs: (i) similarity 
score and (ii) a fi le containing the sequence alignment of the 
two active sites. The similarity score (S) is simply the ratio of 
the scoring function determined by comparing a protein target 
active site against a reference active site (Sab) from the CPASS 
database, with the scoring function of a protein target active site 
compared against itself (Saa). 
S = Sab /  Saa × 100                              (2)
A similarity score is calculated for each comparison. Us-
ing the entire CPASS database would result in 26,000 similari-
ty scores. The similarity score is not symmetrical and depends 
on the order of the comparison. This arises because the scoring 
function is dependent on the size or the number of amino acids 
that defi nes the active site. 
Consider comparing a hypothetical or novel protein com-
plexed with adenine against the CPASS database. It is plausi-
ble that reference proteins that are complexed with ATP, NAD, 
or FAD may exhibit a high similarity based on a near complete 
overlap with the adenine component of their ligand-defi ned ac-
tive sites with the adenine complexed to the hypothetical pro-
tein. The reverse comparison would yield a signifi cantly small-
er similarity score, since a single adenine would only represent 
a subset of an active site defi ned by ATP, NAD, or FAD. 
To simplify the utility of CPASS and the interpretation of the 
CPASS output, a web-based interface has been developed that 
will be accessible through our website http://bionmr-c1.unl.edu  
(Fig. 2). The CPASS output contains a list of all the aligned ac-
tive sites, with a similarity score above the cut-off, typically 
30%, that is directly linked to a graphical display of the aligned 
active sites, using Chime.43,44 Additional information listed is 
the sequence alignment, the Cα rmsd-weighted function, the 
rmsd-weighted BLOSUM62 scores, and the protein and ligand 
identity from the PDB fi le. 
Fig. 2. Screen shots of the web interface to CPASS (a) entry form for active site comparison, (b) list of the active sites with the highest similarity to 
target protein, (c) graphical display of the aligned active sites’ structures, sequence alignments, Ca rmsd weighted function, rmsd-weighted BLOSUM62 
scores, and information about the aligned protein and its bound ligand. A hyperlink in the similarity list in (b) links to the display in (c).
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RESULTS AND DISCUSSION 
Validation of CPASS 
The primary application of the CPASS program is to aid in 
the functional annotation of hypothetical or novel proteins by 
comparing experimentally-defi ned ligand based active sites. 
This is based on the premise that the sequence and structural 
composition of a protein active site is uniquely defi ned by the 
biological function of the protein. It is generally accepted that 
a global similarity in either sequence or tertiary fold of a pro-
tein is correlated to its function.7 The underlying hypothesis in 
the application of CPASS is that a biological function may also 
be assigned to a protein, based on similarities in the character-
istics of experimentally defi ned ligand based active sites in the 
absence of global sequence or structure homology.45 
To address this hypothesis and validate the utility of the 
CPASS program, a general comparison of active site structures 
with known outcomes was conducted. The resolving power of 
ligand-defi ned active sites to identify protein function was as-
certained by comparing ATP and pyridoxal 5'-phosphate (PLP) 
active sites from a variety of functionally distinct proteins. One 
hundred and seventy six ATP binding sites and 294 PLP bind-
ing sites were identifi ed from structures in the PDB. The ATP 
binding sites were clustered into 19 functional classes based on 
the enzyme classifi cation in the BRENDA database.46,47 Sim-
ilarly, the PLP binding sites were clustered into 20 functional 
classes. The ATP binding sites were compared with each oth-
er for a total of 30,976 comparisons. The PLP binding sites 
were compared with each other for a total of 86,436 compari-
sons. The calculations took ~1–2.5 days on a 16-node Beowulf 
Linux cluster, where each comparison averaged ~ 40 s. For each 
protein, the best match for each functional class was identifi ed. 
Comparisons between proteins with ≥ 95% sequence similari-
ty were excluded from identifying the best match. As an exam-
ple, a phospho-transferase (PDB ID:1TQP) from Archaeoglobus 
fulgidus exhibits the highest similarity (52%) to a phosphotrans-
ferase (PDB ID:1PHK) from Oryctolagus cuniculus. Global se-
quence alignment of 1TQP with 1PHK using ClustalW48 yield-
ed an alignment score of only 8%. Conversely, the best match 
of a phosphotransferase to an alkyltransferase (PDB ID:1G64) 
is 15%. As anticipated, a higher average similarity score was al-
ways seen between proteins of identical function (diagonal) than 
functionally distinct proteins (off-diagonal) (Fig. 3). The results 
were independent of the type of ligand (ATP, PLP) or protein 
function. Nevertheless, the relative range of average similari-
ty scores did vary by the function of the proteins. Comparison 
of ATP or PLP binding sites from functionally identical proteins 
resulted in relatively high similarity scores (~40–100%). Con-
versely, functionally distinct proteins generally yielded relative-
ly low similarity scores despite binding the same ligand. Thus, 
the highest observed similarity score for a hypothetical protein 
determined by comparison against the CPASS database would 
identify the protein(s) that has the highest probability of sharing 
a similar function with the hypothetical protein. 
Fig. 3. A contour plot of the percent similarity determined from the CPASS analysis of (a) 294 pyridoxal 5'-phosphate binding sites and (b)176 
ATP binding sites are plotted according to protein function. The diagonal compares proteins of identical function. Contours are plotted in 10% 
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Comparison of the ATP and PLP similarity plots (Fig. 3) 
clearly indicates a difference in the absolute magnitude of some 
of the off-diagonal peaks. A number of the PLP off-diagonal 
peaks indicate a 50–60% similarity between different function-
al classes, whereas the maximum off-diagonal peaks are 30–
40% in the ATP plot. Also, more of the off-diagonal peaks are 
>30% in the PLP plot, where a majority of the ATP off-diagonal 
peaks are <30%. These observations refl ect the relative evolu-
tionary pathways of the ATP and PLP binding sites. Evolution-
ary analysis of PLP-dependent enzymes indicates only four in-
dependent lineages (completely different folds) resulting from 
two distinct divergent events (reaction specifi c, substrate spe-
cifi c) from a primordial PLP protein.49 All PLP-dependent en-
zymes catalyze amino acid metabolism and as a result share 
important mechanistic features that include (i) covalent bond 
between PLP and a lysine residue, (ii) amino acid binding site 
proximal to PLP for transimination with substrate, (iii) forma-
tion of a planer coenzyme-substrate aldimine adduct, and (iv) 
optimization of noncovalent interaction between the protein 
and the PLP–substrate complex. These mechanistic require-
ments suggest that PLP caused evolutionary restraints relative 
to ATP-dependent proteins. Thus, the evolutionary analysis of 
PLP-dependent enzymes that indicates close relationships with-
in this protein family is consistent with the high off-diagonal 
similarities observed in the CPASS analysis, using a narrow-
er functional classifi cation. As an example, CPASS indicates 
a 63.1% similarity between hydroxymethyl transferase (E.C. 
2.1.2) and amino acid acetyl transferase (E.C. 2.3.1), which are 
both members of the α-family and closely related in the PLP 
phylogenic map.49 
Although PLP-dependent enzymes appear to share a com-
mon evolutionary pathway, a similar relationship is not expect-
ed across the more functionally diverse family of ATP binding 
proteins. Clearly, the signifi cant differences in function be-
tween actin and kinase proteins would imply a very distinct and 
unrelated evolutionary pathway. In fact, identifying an evolu-
tionary relationship between divergent members of the kinase 
family alone is challenging.50 These different functional classes 
of ATP binding proteins separately and distinctly optimized an 
ATP binding site specifi c to the functional needs of the protein. 
Any similarity in the ATP binding site would result from con-
vergent evolution.45,51,52 Again, this lack of a strong evolution-
ary relationship between the various ATP binding proteins is 
consistent with the relatively low off-diagonal similarity scores 
observed in the CPASS analysis. 
The value of the CPASS analysis is also illustrated by a com-
parison of the global pair-wise sequence identity determined 
by ClustalW48 for the 176 ATP-binding sites with the CPASS 
similarity score (Fig. 4). A general linear correlation between 
the CPASS and ClustalW alignment scores is expected and ob-
served. Clearly, as the global sequence identity increases, a cor-
responding increase in the similarity of the active sites would 
also occur. This is fundamental to the application of sequence 
alignment to assign function. The two circled areas in the graph 
indicate regions that signifi cantly deviate from this linearity. 
Region (a) corresponds to CPASS similarity scores that are 
signifi cantly higher than the corresponding ClustalW scores. 
This indicates a high similarity in the sequence and structure 
characteristics of active site for proteins with extremely low 
(<20%) sequence alignment. These low sequence alignments 
are not expected to yield a functional annotation, but are consis-
tent with the observation that numerous homologous proteins 
structures exhibit high global sequence diversity.53 Again, by 
emphasizing active site structural alignments with an inherently 
higher level of conservation relative to global sequence align-
ments, an increase in the probability of obtaining a functional 
annotation can be achieved using CPASS. 
Region (b) in Figure 4 corresponds to low CPASS similarity 
for proteins with high sequence alignments. Proteins that have 
multiple ATP binding sites, which are sequence and structural-
ly distinct, will result in low CPASS scores, when these distinct 
active sites are compared. This is an expected result and pro-
vides a negative control for validating CPASS. Of course, the 
overall sequence similarity would be high, even though the two 
ATP binding sites being compared are quite different. 
Functional Annotation of Hypothetical Proteins 
Further validation of the utility of CPASS to assist in the 
functional annotation of hypothetical proteins was ascertained 
by analyzing two structures of hypothetical proteins recently 
reported in the literature that serendipitously contained a bound 
ligand. The 2.0 Å X-ray structure of yeast hypothetical protein 
YBL036C contained a covalently attached pyridoxal 5'-phos-
phate. CPASS comparison against 294 active sites containing 
pyridoxal 5'-phosphate indicated that the best match (42% sim-
ilarity) corresponded to an alanine racemase (Fig. 5). 
The function of YBL036C had been tentatively identifi ed 
as an alanine racemase.54 Comparison of YBL036C against a 
structural database identifi ed alanine racemase and ornithine
Fig. 4. Comparison of the CPASS active site similarity score and 
the global percent sequence similarity determined by ClustalW48 for 
the 176 ATP binding sites. The circled areas represent signifi cant de-
viations from a linear relationship between CPASS and ClustalW in-
dicated by the straight line. Region (a) corresponds to high active site 
CPASS similarity scores for proteins with low global sequence simi-
larity. Region (b) corresponds to proteins with multiple distinct ATP 
binding sites, where CPASS similarity is expected to be low. 
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decarboxylase as globally similar in tertiary fold to YBL036C, 
where all three proteins exhibit a similar TIM-barrel fold. Nev-
ertheless, a poor alignment of YBL036C against alanine race-
mase was obtained using the entire TIM-barrel fold. Also, the 
structure of YBL036C could not be determined by molecular 
replacement using the alanine racemase structure. A brute-force 
alignment using a subset of the alanine racemase that included 
the PLP active site resulted in a signifi cant improvement with 
a 1.72 Å rmsd. Manual comparison of the YBL036C and ala-
nine racemase active sites suggested a signifi cant similarity to 
justify testing for D-alanine racemase activity. YBL036C was 
shown to exhibit D-to l-alanine racemase activity. Thus, the 
CPASS assignment of YBL036C as an alanine racemase is con-
sistent with the previously reported detailed structural and bio-
chemical analysis. 
Similarly, a 2.2 Å X-ray structure of hypothetical protein 
YecO from Haemophilus infl uenzae contained a bound S-adeno-
syl-L-homocysteine and is amenable to CPASS analysis. CPASS 
comparison against 46 structures containing S-adenosylmethi-
onine and one structure containing S-adenosyl-L-homocysteine 
indicated that the best match (35% similarity) corresponded to 
a glycine N-methyltransferase. This example illustrates the use 
of CPASS to compare ligand-defi ned active sites, using related 
but chemically distinct ligand structures. In this case, S-adeno-
syl-L-homocysteine is a processed cofactor (Fig. 5). 
The function of YecO has been identifi ed as a methyl-trans-
ferase.55 Again, this was based primarily on structural compari-
son using DALI56 and VAST,57 along with the presence of S-ad-
enosyl-L-homocysteine. Methlytransferase have extremely low 
sequence homology (3–18%), but most methyltransferase bind 
the cofactor in a similar manner. Glycine N-methyltransferase 
binds S-adenosylmethionine in a drastically different binding 
mode, compared with other methyltransferase, and was iden-
tifi ed as one of the structures most similar to YecO. Again, the 
CPASS assignment of YecO as a methyltransferase is consis-
tent with the previously reported detailed structural analysis. 
CPASS identifi ed glycine N-methyltransferase as exhibiting a 
similar active site structure as YecO is also consistent with this 
previous analysis. These results support the general applica-
tion of the CPASS database and software to assign a biological 
function to novel or hypothetical proteins, by comparing exper-
imentally determined active sites. 
Fig. 5. Top: Comparison of the pyridoxal-5'-phosphate defi ned active sites for (a) yeast hypothetical protein YBL036C (PDB ID:1B54) and 
(b) alanine racemase (PDB ID:1RCQ). Bottom: Comparison of the S-adenosyl-L-homocysteine defi ned active site for (c) hypothetical protein 
YecO from Haemophilus infl uenzae (PDB ID:1IM8) with the (d) S-adenosylmethionine defi ned active site for glycine N-methyltransferase (PDB 
ID:1KIA). The residues aligned by CPASS are colored blue in the structures, and the active site sequence alignments are shown below the 
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Comparison of CPASS to Other Methods 
CPASS shares a similarity in concept to other techniques 
that are being developed to infer function for hypothetical pro-
teins.14–19,58 Like CPASS, these approaches are using informa-
tion about the protein’s active site to make a correlation with a 
known protein and assign a function to the unknown protein. 
Nevertheless, the application and details of the CPASS approach 
are fundamentally distinct from these other methods. For exam-
ple, the ‘‘Fuzzy Functional Form’’ (FFF) described by Fetrow 
and Skolnick59 was developed to provide genome-wide func-
tional annotation, using only the amino acid sequences for each 
hypothetical protein. The success of the FFF approach is mon-
itored by the number of correctly annotated proteins instead of 
its ability to correctly annotate a specifi c protein, which is the 
objective of CPASS. Thus, the computational speed and broad 
coverage requirements of FFF result in signifi cant compromis-
es relative to CPASS that included a simplifi ed and limited ac-
tive site comparison and the complete absence of experimen-
tal data. The three-dimensional protein structure, the identity of 
the active site, and protein–ligand complex structures are un-
knowns in FFF. In fact, the aim of FFF is to predict the structure 
and identity of the active site simply from the sequence of the 
hypothetical protein and a few structure templates for proteins 
of known function.17 This is a very laudable but challenging 
goal. Conversely, CPASS depends on the experimentally deter-
mined structure and the unambiguous ligand-defi ned active site 
to provide functional information for a single protein. 
Briefl y, FFF predicts a 3D structure for each hypothetical 
protein, by threading the sequence into 2–3 structures for pro-
teins of a specifi c function.60 Second, FFF uses a consensus ac-
tive site defi ned from a sequence alignment of functionally an-
notated proteins, where an active site residue must be present 
in ≥ 50% of the aligned sequences. A functional assignment is 
then made if the threaded sequence is consistent with one of the 
template structures and if all the conserved active site residues 
overlap with the structural template. 
Unlike CPASS, only a few highly conserved amino acids are 
used to defi ne an active site instead of a complete description 
for all the active site residues. Conversely, FFF requires that 
the predicted active site for the hypothetical proteins contain an 
exact match with the consensus active site, where CPASS pro-
vides a similarity score that allows for homologous amino acid 
substitution. Again, speed dictates this requirement in FFF, but 
the detailed comparison that is achieved by the precise com-
parison of ~26,000 ligand-defi ned active sites with CPASS is 
lost, potentially resulting in incorrect structural alignments and 
false assignments. Consider a simple hypothetical example, if a 
consensus active site contains a conserved aliphatic amino acid 
(Ala, Ile, Leu, Val), but neither of these residues is consistently 
present (≥50%) in the aligned sequences, then FFF will not in-
clude this descriptor as part of its active site defi nition. As a re-
sult, a hypothetical protein that contains an Arg at this position 
would equally and probably incorrectly match the consensus 
active site. There is no differentiation from other hypothetical 
proteins that correctly contain this conserved amino acid type. 
Conversely, CPASS utilizes each individual active site for the 
sequence alignment, where the presence of Arg would result in 
a negative impact on the CPASS similarity score. 
Furthermore, consider large functional families that contain 
hundreds of members, such as kinases and PTPases. Numer-
ous functional subclasses potentially exist within these large 
families, where a consensus active site across the entire family 
is inappropriate, but accurately delineating membership with-
in the subclasses and correctly defi ning a consensus active site 
for each subclass may be challenging.50 The accuracy of the 
functional assignment for FFF is strongly dependent on the cor-
rect description of these consensus active sites. These issues are 
avoided in CPASS by using the entire ligand-defi ned active site 
for comparison (all the individual kinase, PTPase along with 
other protein active sites are used). CPASS specifi cally iden-
tifi es which protein-ligand complexes in the CPASS database 
and shares a homologous active site with the hypothetical pro-
tein. This aspect of CPASS is more computationally intensive 
relative to FFF, since it requires a comparison of ~26,000 li-
gand-defi ned active sites comprising upwards of ≥ 25 amino ac-
ids each. But, the structural threading is similarly computation-
ally expensive in the FFF protocol requiring a limited number 
of structural templates. 
Other approaches similar to FFF also attempt to predict func-
tion or identify active sites through the use of homology mod-
els based on known protein structures.18,19 These models gen-
erally suffer from an abundance of false positives because of 
the accuracy of the threading procedure. An accurate threaded 
structure requires 60% of residues in the hypothetical sequence 
to occupy structurally analogous sites in the target structure.61 
Thus, the sequence for the hypothetical protein needs to share 
more than 50% sequence identity with the protein structure 
template.62 Nevertheless, any sequence can be threaded into a 
structure template and simply evaluated by an empirical ener-
gy function, resulting in incorrect predicted folds. CPASS does 
not attempt to predict a structure for a hypothetical protein but 
requires the availability of this structure and avoids the uncer-
tainty generated by a predicted structure. Effectively, FFF and 
other similar programs are analogous to global sequence align-
ments, but utilize a structural homology fi lter to refi ne the glob-
al sequence alignment. 
Application of CPASS in Drug Discovery 
An important issue in drug discovery is designing selectivity 
into chemical leads to avoid undesirable activity that may cause 
toxic side-effects in clinical trials.63 Improving the affi nity of 
a chemical lead against a defi ned protein target can be readi-
ly quantifi ed, but determining the relative selectivity against all 
potential targets is impractical. The main challenge is in iden-
tifying proteins that may be inadvertent targets of the chemical 
lead. Again, global sequence or structural homology to the pro-
tein target is the major method of identifying proteins with a po-
tential affi nity to the chemical lead. Unfortunately, this does not 
yield a thorough analysis of the proteome or a prediction of li-
gand affi nity, since the comparison is not specifi c to the active 
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site. CPASS provides an additional approach to identifying po-
tential cross-reactivity between proteins of diverse function by 
identifying related ligand-biding sites. The ATP and PLP bind-
ing-site analysis indicates that the highest observed similarity 
is between proteins of identical function (Fig. 3). Nevertheless, 
there are a number of examples where functionally distinct pro-
teins share >30–40% similarity (off-diagonal), such as ATPases 
and cell division proteins for the ATP binding proteins and hy-
drolyase and ammonia-lyase for the PLP-dependent enzymes. 
Again, CPASS will not provide a complete analysis of the en-
tire proteome, since it is limited to the representative protein 
structures and functions in the PDB. But, CPASS will assist in 
improving the selectivity of chemical leads by expanding the 
list of relevant proteins beyond those proteins that are function-
ally related to the target. Thus, CPASS can identify a broader 
spectrum of proteins to use in biological assays to test for activ-
ity and selectivity against potential drug candidates.
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Table 1S:  List of Ligands and PDB HET Labels Excluded from the CPASS Database 
2-mercaptanol BME, SEO lanthanum LA 
acetate ACT lead PB, PBM 
acetic acid ACY lithium LI 
acetone ACN lutetium LU 
acetonitrile CCN magnesium MG, MO1, MO2, MO3, 
MO4, MO5, MO6 
alcohol IPA manganese MN, MN3, MN5, 
MW1, MW2, MW3, 
MH2, MH3, O4M 
aluminum AL mercury HG, HG1 
amide AF3,NH2,NH4,NH3, NH methanol MOH 
antimony SBO, ND4 methylamine NME 
argon SB methyl phosphinic acid SOM 
arsenic ARS, AST, AR MES MES 
azide AZI molybdenum MOS, MO7, OMO, 
MOO, MM4,  MO, 
4MO, 6MO 
barium BA nickel NI, 3NI, NI1, NI2 
beryllium BEF, BF2, BF4 nickel-iron NFE 
bicarbonate BCT nitogen dioxide 2NO 
borate BO4 nitrate NO3 
boric acid BO3 nitrite NO2 
bromine BR, BRO nitrogen monoxide NMO 
bromomercury HG2 nitrogen oxide NO 
cacodylate CAC osmium OS 
cadmium CD, CD1, CD3, CD5 oxygen O,  OX, OEC, O2, 
OXY, HF5 
calcium CA, OC1, OC2, OC3, OC4, 
OC5, OC6, OC7, 543 
palladium PD 
carbon dioxide CO2 perchlorate LCP 
carbon monoxide CMO peroxide PEO, PER 
cerium CE phosphate 2HP, DPO, FPO,  PI, 
IPS, PO4, 3PO 
cesium CS phosphite PO3 
chlorine CL, CLO, CFO, LCO platinum PCL 
cobalt CO, 3CO, NCO, OCL, OCN, 
OCM, CO5, OCO, CON 
porphyrin HCO 
copper CU, CU1, ICU, CUO, C2C, 
C1O, C2O, CUA, CUZ 
potassium K, KO4 
copper chloride CUL praseodymium PR 
copper-sulfer cluster CUN, CUM rhenium RE, RTC 
cyanide CN, CYN rhodium RHD 
dimethylformamide DMF rithenium RU 
DMSO DMS rubidium RB 
ethanol EOH samarium SM 
ethylene glycol EDO, EGL selenium SE4, SE, MSE 
Prot-00634-2005R1 
europium EU, EU3 silver AG 
fluorine F, FLO sodium NA, NAW, NAO, NA2, 
NA5, NA6 
formic acid FMT strontium SR 
gadolinium GD, GD3 sulfate SOH, SUL 
galluim GA sulfite SO3 
glucosamine NAG sulfur S 
glycerol GOL sulfur dioxide SO2 
gold AU, AU3, AUC sulfur oxide SX 
holimium HO tantalum TBR 
hydrogen H tellerium TE 
hydrosulfuric acid H2S terbium TB 
hydroxy OH, HYD thallium TL 
hypophosphite PO2 tungsten W, WO4, WO5 
indium IN uranyl IUM 
iodine IOD, IDO vanadium V, V7O, VO3, VO4 
iridium IR, IR3, IRI water MTO, DOD, HOH, 
WAT 
iron OF2, HC1, FCO,  FE, FE2, 
OF3, OF1, 2OF, FEL, OFO, 
FEA, FEO 
xenon XE 
iron-sulfur cluster WCC, XCC, NFS, CFM, CFN, 
CLP, FES, F3S, FS3, FS4, 
SF4, FSO 
ytterbium YB 
krypton KR yttrium YT3,  Y1 
glucosamine NAG zinc ZN, ZN2, ZN3, 
various small molecular 
fragments or clusters 
ACE, BUT, CBZ, CO3, CBX, CBM, CM, MCE, CBG, DTN, ETD, ETH, OET, EMC, 
EOX, FOR, HOA, OHE, OME, 2ME, CH3, TML, MCB, CH2, HDZ, TFH, WO2, 
OXO, ZRC, CNB, CN1, CNF, OXA, QTR, CYO, OMB, 2PO, PHS, PPM, PVL, 
SBU, HF3, SFO, SFN, DML, TBU, NTB, ALF, TMA, THJ, SCN, SCC, TFA, MGF, 
TME, CYA, UNX, UNK, UNL, U1, DIS 
 
 
 
